We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

103 hedge funds and large institutions have $677M invested in BioCryst Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 38 increasing their positions, 15 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

153% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 15

152% more call options, than puts

Call options by funds: $11.8M | Put options by funds: $4.71M

94% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 17

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

47% more capital invested

Capital invested by funds: $461M → $677M (+$216M)

17% more funds holding

Funds holding: 88 → 103 (+15)

Holders
103
Holders Change
+15
Holders Change %
+17.05%
% of All Funds
2.96%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.09%
New
33
Increased
38
Reduced
15
Closed
17
Calls
$11.8M
Puts
$4.71M
Net Calls
+$7.14M
Net Calls Change
+$3.88M

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$48.9M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$17M
3
BFA
BlackRock Fund Advisors
California
+$16.2M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$12.9M
5
BIT
BlackRock Institutional Trust
California
+$8.42M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$16.7M
2
TGHSA
TPG Group Holdings (SBS) Advisors
Texas
-$12.3M
3
RCM
RA Capital Management
Massachusetts
-$11.2M
4
DM
Deerfield Management
New York
-$9.61M
5
Millennium Management
Millennium Management
New York
-$4.29M
Name Holding Trade Value Shares
Change 		Change in
Stake
SIM
76
Strategic Investment Management
Virginia
$255K +$195K +20,000 New
Deutsche Bank
77
Deutsche Bank
Germany
$244K -$719K -73,905 -79%
Principal Financial Group
78
Principal Financial Group
Iowa
$208K +$159K +16,296 New
TRCT
79
Tower Research Capital (TRC)
New York
$207K +$145K +14,929 +1,212%
CIBC Private Wealth Group
80
CIBC Private Wealth Group
Georgia
$201K +$154K +15,796 New
Comerica Bank
81
Comerica Bank
Texas
$186K +$10.6K +1,089 +8%
Barclays
82
Barclays
United Kingdom
$182K +$47.8K +4,915 +48%
VKH
83
Virtu KCG Holdings
New York
$182K +$139K +14,321 New
Prudential Financial
84
Prudential Financial
New Jersey
$168K +$128K +13,200 New
Janney Montgomery Scott
85
Janney Montgomery Scott
Pennsylvania
$166K – – –
JIC
86
Joel Isaacson & Co
New York
$153K – – –
SG Americas Securities
87
SG Americas Securities
New York
$132K +$1.58K +162 +2%
BGA
88
Belmont Global Advisors
Texas
$127K – – –
Citigroup
89
Citigroup
New York
$115K +$3.61K +371 +4%
WAM
90
Wolverine Asset Management
Illinois
$77K +$58.9K +6,050 New
VFA
91
Virtus Fund Advisers
Connecticut
$76K +$58.2K +5,979 New
Dimensional Fund Advisors
92
Dimensional Fund Advisors
Texas
$47K +$32.1K +3,300 +871%
Royal Bank of Canada
93
Royal Bank of Canada
Ontario, Canada
$45K – – –
LTFS
94
Ladenburg Thalmann Financial Services
Florida
$38K +$29.2K +3,000 New
PCM
95
Prelude Capital Management
New York
$33K +$25.3K +2,600 New
Teacher Retirement System of Texas
96
Teacher Retirement System of Texas
Texas
$21K – – –
Bank of Montreal
97
Bank of Montreal
Ontario, Canada
$13K – – –
Creative Planning
98
Creative Planning
Kansas
$10K – – –
WA
99
WFG Advisors
Texas
$8K – – –
TDC
100
Thompson Davis & Co
Virginia
$6K +$4.87K +500 New
1 2 3
4
5

BCRX Hedge Fund Activity: Q2 2014 in Review

103 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q2 2014, worth a combined $677M — up 47% from $461M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new BCRX positions and 17 closed out — a net gain of 16 holders — while 38 added to existing stakes and 15 trimmed.

The largest buyer was Baker Bros. Advisors, adding an estimated $48.9M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $16.7M sold.

  • 103 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q2 2014, up from 88 in Q1 2014.
  • Funds reported $677M of BioCryst Pharmaceuticals stock for Q2 2014, up 47% quarter-over-quarter.
  • 33 funds opened new BioCryst Pharmaceuticals positions in Q2 2014 and 17 closed out, a net change of +16 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q2 2014 was Baker Bros. Advisors, an estimated $48.9M added.
  • The largest BioCryst Pharmaceuticals seller in Q2 2014 was T. Rowe Price Associates, an estimated $16.7M sold.

Based on aggregated 13F filings for Q2 2014.